Tags

Type your tag names separated by a space and hit enter

Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
J Neurol. 2018 May; 265(5):1226-1229.JN

Abstract

OBJECTIVE

To investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis.

METHODS

We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis.

RESULTS

In the 2 years prior to first dose of alemtuzumab, 82.8% of the 29 patients had a new lesion on MRI and/or a clinical relapse, with an ARR of 0.67. In the mean 24.7 month follow-up after the first dose of alemtuzumab, 17.2% of patients displayed new disease activity and the ARR was 0.08. 4 out of 5 patients who relapsed did so within 12 month post-first infusion and received a second dose. Of the 24 patients who did not relapse, 8 received a second dose at 1 year and 16 did not. 5 out of all 29 patients developed thyroid disorder.

CONCLUSIONS

Given that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen.

Authors+Show Affiliations

Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Touro College of Osteopathic Medicine, 60 Prospect Avenue, Middletown, NY, 10940, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA.Division of Neurology, New York-Presbyterian/Weill Cornell Medicine, 1305 York Avenue, Suite Y-217, New York, NY, 10021, USA. jsp9007@med.cornell.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29666985

Citation

Kocsik, Alexandra S., et al. "Induction of Disease Remission With One Cycle of Alemtuzumab in Relapsing-remitting MS." Journal of Neurology, vol. 265, no. 5, 2018, pp. 1226-1229.
Kocsik AS, Klein DE, Liedke M, et al. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. J Neurol. 2018;265(5):1226-1229.
Kocsik, A. S., Klein, D. E., Liedke, M., Kaunzner, U. W., Nealon, N. M., Gauthier, S. A., Vartanian, T., & Perumal, J. S. (2018). Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. Journal of Neurology, 265(5), 1226-1229. https://doi.org/10.1007/s00415-018-8845-4
Kocsik AS, et al. Induction of Disease Remission With One Cycle of Alemtuzumab in Relapsing-remitting MS. J Neurol. 2018;265(5):1226-1229. PubMed PMID: 29666985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. AU - Kocsik,Alexandra S, AU - Klein,David E, AU - Liedke,Maryana, AU - Kaunzner,Ulrike W, AU - Nealon,Nancy M, AU - Gauthier,Susan A, AU - Vartanian,Timothy, AU - Perumal,Jai S, Y1 - 2018/04/17/ PY - 2018/01/02/received PY - 2018/03/22/accepted PY - 2018/03/21/revised PY - 2018/4/19/pubmed PY - 2018/9/21/medline PY - 2018/4/19/entrez KW - Alemtuzumab KW - Disease-modifying therapy KW - Multiple sclerosis KW - Relapse SP - 1226 EP - 1229 JF - Journal of neurology JO - J Neurol VL - 265 IS - 5 N2 - OBJECTIVE: To investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis. METHODS: We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis. RESULTS: In the 2 years prior to first dose of alemtuzumab, 82.8% of the 29 patients had a new lesion on MRI and/or a clinical relapse, with an ARR of 0.67. In the mean 24.7 month follow-up after the first dose of alemtuzumab, 17.2% of patients displayed new disease activity and the ARR was 0.08. 4 out of 5 patients who relapsed did so within 12 month post-first infusion and received a second dose. Of the 24 patients who did not relapse, 8 received a second dose at 1 year and 16 did not. 5 out of all 29 patients developed thyroid disorder. CONCLUSIONS: Given that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen. SN - 1432-1459 UR - https://www.unboundmedicine.com/medline/citation/29666985/Induction_of_disease_remission_with_one_cycle_of_alemtuzumab_in_relapsing_remitting_MS_ L2 - https://dx.doi.org/10.1007/s00415-018-8845-4 DB - PRIME DP - Unbound Medicine ER -